Lawrence Miller, Apnimed CEO

Ap­n­imed touts PhI­Ib da­ta for lead sleep ap­nea pro­gram, prepar­ing to ad­vance to piv­otal stud­ies

Not six months af­ter rais­ing cash to take a drug for ob­struc­tive sleep ap­nea through Phase III tri­als, Cam­bridge’s Ap­n­imed is set­ting the stage with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.